The Benefit and Future of Pharmacogenetics

Samardžić, Janko; Štrac, Dubravka Švob; Anker, John N. van den

doi:10.1007/978-3-319-47609-4_38

Cited by 2 publications

(9 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Jedan od brojnih, ako ne i presudnih faktora, koji utiču na odgovor na farmakoterapiju je genetički profil pacijenta. Naime, savremena metodologija omogućila je sekvenciranje gena, uključujući one koji kodiraju proteine koji utiču na farmakokinetiku (FK) i farmakodinamiku (FD) lekova [6]. Rasvetljavanje kompleksne veze između genetičke osnove i odgovora na terapiju postaje sve značajnije u razvoju novih strategija u lečenju i prevenciji bolesti.…”

Section: Uvodunclassified

“…Rasvetljavanje kompleksne veze između genetičke osnove i odgovora na terapiju postaje sve značajnije u razvoju novih strategija u lečenju i prevenciji bolesti. U tom smislu, rutinska farmakogenetička testiranja imaju za cilj da omoguće lekaru u kliničkoj praksi individualizaciju doznog režima i bolju predikciju terapijskog odgovora, kako u smislu efikasnosti, tako i u smislu bezbednosti primenjenog leka [6,7].…”

Section: Uvodunclassified

“…One of the many, if not the crucial factor that influences the response to pharmacotherapy is a patient's genetic profile. Modern methodology has enabled the sequencing of genes, including protein-coding genes that influence the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs [6]. Shedding light on the complex connection between a genetic basis and response to therapy is becoming increasingly important in developing new strategies in the treatment and prevention of diseases.…”

Section: Farmakogenetika Kao Kritična Komponenta Personalizovane Medimentioning

confidence: 99%

“…Shedding light on the complex connection between a genetic basis and response to therapy is becoming increasingly important in developing new strategies in the treatment and prevention of diseases. In this sense, routine pharmacogenetic testing is aimed at enabling physicians to individualize dosage regimens in clinical practice and better predict therapeutic responses, both in terms of efficacy and in terms of the safety of the administered drug [6,7].…”

Section: Farmakogenetika Kao Kritična Komponenta Personalizovane Medimentioning

confidence: 99%

“…FARmAkOgENETIkA ANTIdEPREsIvA -kORAk kA INdIvIduAlIzACIJI TERAPIJE Certain genetic polymorphisms encode different proteins that determine the PK, such as enzymes for drug metabolism, or the PD, such as receptors, enzymes, intracellular messengers, and other target molecules for drug effects [6]. The better understanding of the interaction between the genome and etiopathogenesis and the disease therapy has led to the development of pharmacogenomics, which describes multiple variations and the influence of the genome, as a whole, on drug properties, as well as of pharmacoepigenetics as a new discipline that studies ways in which epigenetic mechanisms lead to variations in response to therapy [9,10].…”

Section: Pharmacogenetics Of Antidepressants -A Step To Individualizementioning

confidence: 99%

See 4 more Smart Citations

Pharmacogenetics of antidepressants: A step to individualized therapy

Samardžić¹

2020

Srpski medicinski časopis Lekarske komore

View full text Add to dashboard Cite

Farmakogenetika analizira interindividualne razlike koje dovode do varijabilnog odgovora pacijenata na primenjenu terapiju, sa ciljem da ukaže na koji način pojedini geni i interindividualne genetičke varijacije mogu da utiču na farmakokinetiku i farmakodinamiku lekova. Ona je kritična komponenta personalizovane medicine u psihofarmakologiji. Najveći broj dosadašnjih ispitivanja ukazuje na veliki potencijal farmakogenetičkih ispitivanja prilikom individualizacije terapije antidepresivima. Klinički značaj je, do sada, pokazalo utvrđivanje genetičkog profila i metaboličkog fenotipa za CYP2C19 kod pacijenata na escitalopramu i sertralinu, odnosno CYP2C19 i CYP2D6 kod pacijenata na amitriptilinu. Iako manje ispitana, farmakodinamička varijabilnost nije ništa manje značajna od farmakokinetičke. Polimorfizmi serotoninskog transportera u značajnoj meri utiču na terapijski odgovor na selektivne inhibitore preuzimanja serotonina. Farmakogenetički pristup predstavlja inovativni model u razumevanju heterogenosti terapijskog odgovora na antidepresive. Prednost ovakvog pristupa je nepromenjljivost genotipa u vremenu. S druge strane, postoje brojni izazovi i ograničenja za rutinsko izvođenje ovih analiza, poput dostupnosti ovih testova i složenosti interpretacije rezultata. Učinak leka je kompleksan fenomen i pojedinačne mutacije u pojedinačnim genima ne mogu objasniti svu varijabilnost psihofarmakoterapije. Iako farmakogenetika nedvosmisleno ima veliki potencijal u razvoju lekova i individualizaciji terapije, neophodna su dalja istraživanja da bi se ovaj potencijal u potpunosti primenio u kliničkoj praksi.

show abstract

Section: Uvodunclassified

Section: Farmakogenetika Kao Kritična Komponenta Personalizovane Medimentioning

confidence: 99%

Section: Farmakogenetika Kao Kritična Komponenta Personalizovane Medimentioning

confidence: 99%

Section: Pharmacogenetics Of Antidepressants -A Step To Individualizementioning

confidence: 99%

See 3 more Smart Citations

Pharmacogenetics of antidepressants: A step to individualized therapy

Samardžić¹

2020

Srpski medicinski časopis Lekarske komore

View full text Add to dashboard Cite

show abstract

The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy

Radosavljević

Štrac

Jančić

et al. 2023

Genes

View full text Add to dashboard Cite

Pharmacotherapy for neuropsychiatric disorders, such as anxiety and depression, has been characterized by significant inter-individual variability in drug response and the development of side effects. Pharmacogenetics, as a key part of personalized medicine, aims to optimize therapy according to a patient’s individual genetic signature by targeting genetic variations involved in pharmacokinetic or pharmacodynamic processes. Pharmacokinetic variability refers to variations in a drug’s absorption, distribution, metabolism, and elimination, whereas pharmacodynamic variability results from variable interactions of an active drug with its target molecules. Pharmacogenetic research on depression and anxiety has focused on genetic polymorphisms affecting metabolizing cytochrome P450 (CYP) and uridine 5’-diphospho-glucuronosyltransferase (UGT) enzymes, P-glycoprotein ATP-binding cassette (ABC) transporters, and monoamine and γ-aminobutyric acid (GABA) metabolic enzymes, transporters, and receptors. Recent pharmacogenetic studies have revealed that more efficient and safer treatments with antidepressants and anxiolytics could be achieved through genotype-guided decisions. However, because pharmacogenetics cannot explain all observed heritable variations in drug response, an emerging field of pharmacoepigenetics investigates how epigenetic mechanisms, which modify gene expression without altering the genetic code, might influence individual responses to drugs. By understanding the epi(genetic) variability of a patient’s response to pharmacotherapy, clinicians could select more effective drugs while minimizing the likelihood of adverse reactions and therefore improve the quality of treatment.

show abstract

The Benefit and Future of Pharmacogenetics

Cited by 2 publications

References 110 publications

Pharmacogenetics of antidepressants: A step to individualized therapy

Pharmacogenetics of antidepressants: A step to individualized therapy

The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy

Contact Info

Product

Resources

About